Kengreal (cangrelor) / Chiesi - LARVOL DELTA

Factors influencing the interpretation of meta-analytic findings in cangrelor research. (PubMed, Crit Care) - No abstract available

Journal • Cardiovascular • Myocardial Infarction

Efficacy and Safety of Very-Low-Dose Cangrelor Following Acute Neuroendovascular Intervention (SCCM 2026) - "Very low dose cangrelor may be effective in preventing thrombotic complications with a low rate of symptomatic bleeding events in patients undergoing neuroendovascular procedures. The incorporation of platelet function testing may optimize antiplatelet selection and dosing after a neuroendovascular procedure."

Clinical • Cardiovascular • Ischemic stroke • Thrombosis

Use of Cangrelor and Platelet Reactivity Unit Monitoring in Patients With Acute Ischemic Stroke (SCCM 2026) - "Cangrelor may be a safe alternative antiplatelet agent in patients who could not receive oral P2Y12 inhibitors in acute ischemic stroke. PRU assay monitoring could be considered."

Clinical • Cardiovascular • Ischemic stroke

Parenteral Antiplatelet Use in the Neurocritical Care Patient Population and Associated Outcomes (SCCM 2026) - "There were eight bleeding events in the cangrelor cohort and one bleeding event in the tirofiban cohort with one instance of a new or recurrent stroke seen in each. These agents were used for appropriate indications with doses seen in previous literature. Our safety and efficacy data for the use of cangrelor and tirofiban in the neurocritical care population seems consistent with previous literature; however, larger prospective studies with well-balanced cohorts are needed to draw conclusions on whether either parenteral antiplatelet agent has better safety and efficacy profiles compared to the other."

Clinical • Cardiovascular

SURVIVAL BENEFIT OF PLATELET REACTIVITY GUIDED CANGRELOR IN MECHANICAL CIRCULATORY SUPPORT (ACC 2026) - "The prevalence of bleeding complications was high in patients with cardiogenic shock on mechanical circulatory support. PRU-adjusted cangrelor dosing allowed patients to be bridged from MCS and improved survival, however this was not explained by lower bleeding complications. Further studies are warranted to assess improved outcomes in this high-risk population."

Cardiovascular • Myocardial Infarction

PERICARDIAL PRIMARY EFFUSION LYMPHOMA PRESENTING AS ACUTE CORONARY SYNDROME WITH IMMEDIATE STENT THROMBOSIS AND MALIGNANT VENTRICULAR TACHYCARDIA (ACC 2026) - "He was loaded with aspirin and underwent emergent angiography revealing 99% proximal right coronary artery occlusion...Right femoral access was re-established, and he subsequently developed sustained ventricular tachycardia (VT) requiring defibrillation and amiodarone...He received a 2-hour cangrelor infusion, followed by clopidogrel 600mg, and intravenous heparin... Pericardial lymphoma can rarely manifest as ACS with immediate stent thrombosis and ischemia-driven VT. Recognizing malignancy-related hypercoagulability is critical as management may require intensified antithrombotic therapy beyond standard PCI protocols."

Acute Coronary Syndrome • Cardiovascular • Hematological Malignancies • Lymphoma • Monoclonal Gammopathy • Pulmonary Embolism • Respiratory Diseases • Thrombosis • Ventricular Tachycardia

THE YOUNG AND THE RESTLESS ARTERY: A RARE CASE OF SCAD IN A YOUNG PATIENT WITH BOTH KAWASAKI DISEASE AND LUPUS (ACC 2026) - "Heparin and cangrelor drips were started... Patients with multiple risk factors for SCAD or prior vascular injury may be at heightened risk and SCAD should always be considered in a young person presenting with chest pain even without traditional ASCVD risk factors."

Clinical • Cardiovascular • CNS Disorders • Coronary Artery Disease • Depression • Genetic Disorders • Hematological Disorders • Immunology • Inflammatory Arthritis • Lupus • Thrombosis

CANGRELOR VERSUS ORAL P2Y12 INHIBITORS IN ACUTE CORONARY SYNDROME WITH CARDIOGENIC SHOCK OR CARDIAC ARREST: A SYSTEMATIC REVIEW AND META-ANALYSIS (ACC 2026) - "In ACS with shock or cardiac arrest, Cangrelor reduces all-cause mortality but increases major bleeding compared with oral P2Y12 inhibitors."

Retrospective data • Review • Acute Coronary Syndrome • Cardiovascular • Hematological Disorders • Thrombosis

BLEEDING RISK WITH INTRAVENOUS CANGRELOR BRIDGING VERSUS DIRECT ORAL DUAL ANTIPLATELET THERAPY IN OUT-OF-HOSPITAL CARDIAC ARREST PATIENTS UNDERGOING EXTRACORPOREAL MEMBRANE RESUSCITATION AND PERCUTANEOUS CORONARY INTERVENTION (ACC 2026) - "In this ECPR PCI cohort, cangrelor bridging did not increase bleeding compared with direct oral DAPT initiation. Mean PRBC transfusion requirements were similar between groups, and early differences were not statistically significant."

Clinical • Cardiovascular

ACUTE LEFT MAIN THROMBOTIC OCCLUSION IN A YOUNG PATIENT WITH DIFFUSE CORONARY ECTASIA (ACC 2026) - "Cangrelor was transitioned to eptifibatide and heparin before discharge on DAPT. Acute LM thrombosis in diffuse ectasia is complex. Balloon angioplasty with adjunctive pharmacologic and mechanical support can stabilize patients when stenting is not feasible. Individualized management is critical in this rare but lethal scenario."

Clinical • Atherosclerosis • Cardiovascular • CNS Disorders • Depression • Gout • Hematological Disorders • Hypertension • Inflammatory Arthritis • Thrombosis

THE QUIET TIME BOMB: KAWASAKI DISEASE AND ITS ROLE IN ACUTE CORONARY SYNDROME (ACC 2026) - "The patient was managed medically with tirofiban transitioned to cangrelor, then discharged on dual therapy with clopidogrel and warfarin (INR goal 2-3). Kawasaki disease related coronary aneurysms present unique challenges for revascularization due to ectasia, calcification, thrombus, and competitive flow. In such cases, multidisciplinary evaluation and tailored medical therapy remain central to management."

Acute Coronary Syndrome • Cardiovascular • Myocardial Infarction • Thrombosis • Vasculitis

ESOPHAGEAL HEMATOMA CAUSING COMPLETE OBSTRUCTION: A RARE COMPLICATION OF TRANSESOPHAGEAL ECHOCARDIOGRAPHY DURING LEFT ATRIAL APPENDAGE OCCLUSION (ACC 2026) - "She was discharged on aspirin, clopidogrel and apixaban with plans to de-escalate to apixaban and clopidogrel after one week...Anticoagulation was held, intravenous cangrelor and total parenteral nutrition was started because the patient had complete esophageal obstruction. Imaging follow-up in one week showed resolution of the mass confirming the etiology to be bleeding secondary to TEE. This case underscores the importance of considering esophageal hematoma as a critical differential diagnosis for dysphagia in patients on antithrombotic therapy following TEE-guided procedures."

Atrial Fibrillation • Cardiovascular • Coronary Artery Disease • Gastrointestinal Disorder • Thrombosis

POST MYOCARDIAL INFARCTION VENTRICULAR SEPTAL DEFECT (ACC 2026) - "Cardiothoracic surgery proceeded with VSD patch repair plus CABG×2 on post-PCI day 8 using a cangrelor bridge to DAPT... This case highlights the value of invasive hemodynamics with confirmatory echocardiography for diagnosing post MI VSD. Early recognition and surgical repair are critical for survival."

Cardiovascular • Hypotension • Myocardial Infarction • Pulmonary Disease

ASSOCIATION BETWEEN CANGRELOR USE AND CLINICAL OUTCOMES IN PATIENTS WITH CARDIOGENIC SHOCK (ACC 2026) - "Use of cangrelor in patients with CS undergoing PCI on day 1 of admission was independently associated with lower in-hospital mortality."

Clinical • Clinical data • Cardiovascular

COMPARISON OF TIROFIBAN VERSUS CANGRELOR AS A TEMPORARY ANTIPLATELET BRIDGING AGENT FOR CORONARY STENT PROTECTION (ACC 2026) - "Conclusions of the study are currently pending."

Cardiovascular • Hematological Disorders • Thrombosis

BLEEDING RISK ASSESSMENT WITH CARDIOVASCULAR SURGERY ON CANGRELOR AND EXTRACORPOREAL SUPPORT (ACC 2026) - "Patients will be categorized into two groups: (1) triple antithrombotic therapy (aspirin, cangrelor and anticoagulant) and (2) dual antithrombotic therapy. In progress"

Surgery • Cardiovascular • Hematological Disorders • Myocardial Infarction • Thrombosis

Real-world adoption of the 2023 European Society of Cardiology guidelines regarding antiplatelet strategies in acute coronary syndromes: Insights from the European READAPT-2 survey. (PubMed, Int J Cardiol) - "Findings from READAPT-2 reveal a persistent gap between guideline awareness and clinical practice, highlighting the need for tailored implementation and education strategies to support a broader guideline uptake."

Journal • Real-world evidence • Acute Coronary Syndrome • Cardiovascular • Myocardial Infarction

The use of mechanical thrombectomy in patients with STEMI and large thrombus burden: design and rationale of the NATURE trial. (PubMed, Cardiovasc Revasc Med) - P=N/A | "Randomization is stratified by site, time from symptom onset (≤ 3 versus >3 h) and intended use of parenteral antiplatelet agents (i.e. glycoprotein IIb/IIIa inhibitors or cangrelor)...The NATURE trial is the first randomized clinical trial aimed at investigating if enVast-assisted mechanical thrombectomy as adjunctive reperfusion strategy is safe and may reduce infarct size in STEMI patients with LTB undergoing primary PCI. TRIAL REGISTRATION: ClinicalTrials.gov number, NCT04969471."

Clinical • Journal • Cardiovascular • Myocardial Infarction • Thrombosis

Safety and Feasibility of Same-Admission Transcarotid Arterial Revascularization Prior to Heart Surgery for Patients Presenting With Concurrent, Severe Carotid Artery Stenosis, and Surgical Cardiac Disease. (PubMed, HCA Healthc J Med) - "Bridging anticoagulation treatment included aspirin and either heparin infusion (60.0%, n = 9), intravenous antiplatelet therapy such as cangrelor or eptifibatide (33.33%, n = 5), or subcutaneous enoxaparin (6.67%, n = 1). In our experience, a range of anticoagulation bridging therapies did not result in apparent stent thrombosis and can be employed until the cardiac surgeon deems it safe to initiate oral dual antiplatelet therapy. Further studies with larger datasets are required to support the broader adoption of TCAR prior to heart surgery in patients with concurrent, severe cardiac and carotid disease."

Journal • Anesthesia • Cardiovascular • Coronary Artery Disease • Heart Failure • Hematological Disorders • Myocardial Infarction • Thrombosis

Hippocampal GPR17 is involved in chronic restraint stress-induced depressive-like behaviors by regulating neuroinflammation and glutamatergic activity in mice. (PubMed, Int Immunopharmacol) - "Moreover, molecular docking revealed that fluoxetine binds to GPR17. We also found that hippocampal glutamatergic neuronal activity is required for antidepressant-like effects of GPR17 antagonist cangrelor. These results suggest that GPR17 regulates chronic stress-induced depressive-like behaviors and hippocampal synaptic transmission through the TLR4/NF-κB/NLRP3 signaling pathway, establishing it as a promising novel therapeutic target for depression."

Journal • Preclinical • CNS Disorders • Depression • Inflammation • Psychiatry • NLRP3 • TLR4

Cangrelor in ST-segment elevation myocardial infarction with high on-treatment platelet reactivity: a pilot randomized trial. (PubMed, J Thromb Thrombolysis) - No abstract available

Journal • Cardiovascular • Myocardial Infarction

Optimizing Periprocedural Antiplatelet Therapy: Clinical Outcomes Of Intravenous Versus Oral P2y12 Inhibitors In Neurovascular and Cardiovascular Interventions (AAN 2026) - "Objective: To evaluate whether intravenous (IV) cangrelor offers clinical advantages over oral P2Y12 inhibitors (ticagrelor, prasugrel) in periprocedural antiplatelet therapy during cardiovascular and neurovascular interventions. Cangrelor offers a rapid-onset, safe alternative to oral P2Y12 inhibitors, reducing early thrombotic complications in PCI. Its potential in acute neurointerventions is promising but unproven, limited by lack of randomized data. A unified IV protocol combining thrombolysis (e.g., tenecteplase) and antiplatelet therapy (e.g., cangrelor) may streamline emergent care."

Clinical • Clinical data • Cardiovascular • Cerebral Hemorrhage • CNS Disorders • Hematological Disorders • Myocardial Infarction • Thrombosis

REPERFUSE: REperfusion With P2Y12 Inhibitors in Addition to mEchanical thRombectomy for perFUsion Imaging Selected Acute Stroke patiEnts (clinicaltrials.gov) - P3 | N=368 | Recruiting | Sponsor: Fondation Ophtalmologique Adolphe de Rothschild | Trial completion date: Jan 2027 ➔ Sep 2030 | Trial primary completion date: Mar 2026 ➔ Mar 2030

Trial completion date • Trial primary completion date • Cardiovascular

Abbreviated Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Lung Transplant Candidates: Striking a Surgical Balance (ISHLT 2026) - "P2Y12 inhibitors were stopped 5 days before listing, and aspirin was continued; post-LTx DAPT was individualized. Short-acting bridges (e.g. Cangrelor) may aid high thrombosis risk patients. Larger longitudinal studies are needed to assess long-term outcomes."

Cardiovascular • Hematological Disorders • Thrombosis • Transplantation

Successful Thrombectomy for Acute Ischemic Stroke in an Infant Supported with a Single Ventricle Assist Device (ISHLT 2026) - "While on SVAD, her anticoagulation regimen consisted of bivalirudin and cangrelor. Her postoperative course was complicated by symptomatic seizures requiring multiple antiepileptics and infusion therapies, with eventual seizure control. At discharge, she demonstrated symmetric motor function in all extremities, and antiepileptics were successfully weaned off in the outpatient setting.Summary This case highlights rapid recognition and successful endovascular thrombectomy for acute ischemic stroke in an infant supported with SVAD, resulting in favorable neurologic recovery."

Cardiovascular • CNS Disorders • Epilepsy • Heart Failure • Hematological Disorders • Ischemic stroke